Vytrus continues to grow. The company dedicated to the sale of cosmetic active ingredients derived from plant biotechnology has registered a new increase in sales in the first nine months of 2026. The company has grown by 75% in the first 9 months of 2025 compared to the same period in 2024, achieving a turnover of more than 6.40 million euros.
Vytrus' sales over the last 12 months stand at 7.8 million euros, and the figure reached in July, August, and September also exceeded 2.07 million euros, increasing by almost 75% compared to the same period in 2024. As for EBITDA, it has increased by 120% compared to the same period in 2024 and reached a figure of 3.2 million euros.
The company is present in 49 countries and continues to grow in all the geographic areas where it operates. In the European Union, including Spain, sales have grown by 80% up to September of this year; in the United States, by 63%, and in Asia-Pacific is where they have experienced their most notable growth: almost 120%. Latin America, on the other hand, has moderated its growth with a modest increase of 12%.
Vytrus's sales boom, as explained by the company, is partly due to its Exosomic Peptides technology, which "drove strong sales growth through September". This ingredient has been widely popular in the formulation of anti-aging products and hair care related products.